BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31182661)

  • 1. Best Practices for
    Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
    J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
    Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
    AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
    [No Abstract]   [Full Text] [Related]  

  • 5. Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan.
    Gill HS; Tade F; Greenwald DT; Yonover PM; Savir-Baruch B
    Clin Nucl Med; 2018 Jan; 43(1):23-24. PubMed ID: 29189374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Seierstad T; Hole KH; Tulipan AJ; Strømme H; Lilleby W; Revheim ME; Hernes E
    PET Clin; 2021 Apr; 16(2):167-176. PubMed ID: 33648662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Additional Primary Neoplasms on
    Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
    J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
    Kim EH; Siegel BA; Teoh EJ; Andriole GL;
    Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
    Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
    J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate Cancer Imaging with 18F-Fluciclovine.
    Savir-Baruch B; Schuster DM
    PET Clin; 2022 Oct; 17(4):607-620. PubMed ID: 36229104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of Prostate Cancer Using Fluciclovine.
    Savir-Baruch B; Zanoni L; Schuster DM
    PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Utility of
    Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
    Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer.
    Savir-Baruch B; Banks KP; McConathy JE; Molchanova-Cook OP; Parent EE; Takalkar A; Tulchinsky M; Yu JQ; Subramaniam RM; Schuster DM
    Clin Nucl Med; 2018 Dec; 43(12):909-917. PubMed ID: 30325827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA-targeted Radiotracers versus
    Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
    Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extraprostatic Uptake of
    Robertson MS; Sakellis CG; Hyun H; Jacene HA
    AJR Am J Roentgenol; 2020 Mar; 214(3):641-648. PubMed ID: 31939697
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
    Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
    South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review discussing fluciclovine (
    Zanoni L; Bossert I; Matti A; Schiavina R; Pultrone C; Fanti S; Nanni C
    Future Oncol; 2018 May; 14(11):1101-1115. PubMed ID: 29359581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.